India's production of certain weight-loss drugs, including Ozempic, may significantly impact the global obesity fight due to their potentially lower cost. The expiration of a patent related to semaglutide, an ingredient in these drugs, is approaching, which could lead to a wave of generic versions in India. This development may have broader economic implications, but the exact effects on the sugar market and other areas are not yet clear.